Patents by Inventor Thomas Spector

Thomas Spector has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190311599
    Abstract: Embodiments relate generally to systems and methods for gas detection. A method may comprise operating a gas detector (102) with a first alarm setting comprising a first predefined threshold; receiving sensed data of oxygen content in the ambient air; when the sensed data is below the first predefined threshold, activating an alarm (110); generating an acknowledgement request asking if the gas detector has entered an inert work zone (122); receiving a response from the user acknowledging that the gas detector has entered an inert work zone; deactivating the alarm; changing the alarm settings of the gas detector to a second alarm setting comprising a second predefined threshold; continuing to receive sensed data of oxygen content in the ambient air; when the sensed data is above the second predefined threshold, activating an alarm; and generating an acknowledgement request for the user asking if the gas detector has entered a normal operation work zone (120).
    Type: Application
    Filed: November 30, 2016
    Publication date: October 10, 2019
    Inventors: Jesper JENSEN, Jacob Thomas SPECTOR
  • Publication number: 20190295407
    Abstract: Embodiments relate generally to gas detector connectivity devices, for example a dongle, to allow for continuous communication of real-time data between a gas detector and a central station. Dongle embodiments typically comprise an IR transceiver, a processor, a wireless interface device, a power source, and a means of attachment. Such dongle embodiments, and their related methods of operation, may allow for retrofitting of legacy gas detectors to provide wireless capabilities.
    Type: Application
    Filed: November 30, 2016
    Publication date: September 26, 2019
    Inventors: Kirk William JOHNSON, Jacob Thomas SPECTOR, Andrew NILSSON, Dean FORD
  • Patent number: 8658618
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: February 25, 2014
    Assignee: Adherex Technologies, Inc.
    Inventor: Thomas Spector
  • Publication number: 20130184232
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Application
    Filed: November 27, 2012
    Publication date: July 18, 2013
    Inventors: Thomas Spector, William Paul Peters, Donald W. Kufe, Brian Huber
  • Patent number: 8318756
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: November 27, 2012
    Assignee: Adherex Technologies, Inc.
    Inventors: Thomas Spector, William Paul Peters, Donald W. Kufe, Brian Huber
  • Publication number: 20110130359
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Application
    Filed: October 14, 2010
    Publication date: June 2, 2011
    Applicant: ADHEREX TECHNOLOGIES, INC.
    Inventor: Thomas Spector
  • Patent number: 7704971
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: April 27, 2010
    Assignee: SmithKlineBeecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Publication number: 20070078106
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Application
    Filed: September 1, 2006
    Publication date: April 5, 2007
    Inventors: Thomas Spector, David Porter, Saad Rahim
  • Patent number: 7119096
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: October 10, 2006
    Assignee: SmithKlineBeecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Publication number: 20060148753
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Application
    Filed: December 5, 2005
    Publication date: July 6, 2006
    Applicant: Adherex Technologies, Inc.
    Inventors: Thomas Spector, William Peters, Donald Kufe, Brian Huber
  • Patent number: 6586440
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynyluracil compounds in the form of tablets or capsules.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: July 1, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Publication number: 20020042392
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C-1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Application
    Filed: October 1, 2001
    Publication date: April 11, 2002
    Inventors: Thomas Spector, David J.T. Porter, Saad G. Rahim
  • Patent number: 6297223
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, iodo, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 aklynyl.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: October 2, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Publication number: 20010025033
    Abstract: Use of uracil reductase inactivators such as 5-substituted uracil derivatives for example 5-ethynyluracil to reduce the toxicity of the anti-HIV nucleoside analogue zidovudine.
    Type: Application
    Filed: April 23, 2001
    Publication date: September 27, 2001
    Inventors: Thomas Spector, David J.T. Porter, Saad George Rahim
  • Patent number: 6268374
    Abstract: The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularly useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: July 31, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Patent number: 6221852
    Abstract: This application relates to pharmaceutical compositions of 5-alkynyl-dideoxyridbouracils which generates 5-alkynyluracils in vivo, which are inactivators of uracil reductase.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: April 24, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Patent number: 6177436
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynuracil.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: January 23, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Patent number: 5817664
    Abstract: The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularily useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Patent number: 5643913
    Abstract: Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: July 1, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Patent number: D800760
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: October 24, 2017
    Assignee: Honeywell International Inc.
    Inventors: Alejandra Gonzalez Delgado, Jacob Thomas Spector